Rapid Disease Course in African Americans with Multiple Sclerosis
Authors
Affiliations
Objective: To investigate utility of a Multiple Sclerosis Severity Scale (MSSS)-based classification system for comparing African American (AA) and white American (WA) multiple sclerosis (MS) subpopulations in the New York State Multiple Sclerosis Consortium (NYSMSC) database. MSSS is a frequency-rank algorithm relating MS disability to disease duration in a large, untreated reference population. Design/
Methods: Distributions of patients in 6 MSSS-based severity grades were calculated for AA and WA registrants.
Results: There were 419 AA and 5,809 WA patients in the NYSMSC, who had EDSS recorded during years 1-30 since symptom onset. Median EDSS was not different in AA and WA (3.5 vs 3.0, p = 0.60), whereas median MSSS in AA was higher than in WA (6.0 vs 4.8, p = 0.001). AA patients were overrepresented in the 2 most severe grades (41.5% vs 29.3% for WA) and underrepresented in the 2 lowest grades (23.4% vs 35.4%; p < 0.001). In multivariable analysis (ordered logistic and median regression), MSSS for AA remained significantly higher than in WA after adjusting for age, gender, disease duration, disease type distribution, and treatment with disease-modifying therapies.
Conclusions: The 6-tiered MSSS grading system is a powerful tool for comparing rate of disease progression in subpopulations of interest. MSSS-based analysis demonstrates that African ancestry is a risk factor for a more rapidly disabling disease course.
Brain lesion characteristics in Chinese multiple sclerosis patients: A 7-T MRI cohort study.
Su L, Zhang Z, Gao C, Guo A, Zhang M, Shi X Ann Clin Transl Neurol. 2024; 12(2):300-310.
PMID: 39575568 PMC: 11822798. DOI: 10.1002/acn3.52256.
Jacobs B, Schalk L, Tregaskis-Daniels E, Tank P, Hoque S, Peter M Mult Scler. 2024; 30(11-12):1544-1555.
PMID: 39301820 PMC: 11520257. DOI: 10.1177/13524585241277018.
Bianchi A, Matranga D, Patti F, Maniscalco L, Pilotto S, Di Filippo M J Neurol. 2024; 271(5):2182-2194.
PMID: 38366072 PMC: 11055772. DOI: 10.1007/s00415-024-12214-6.
Parawira S, Reese V Neurol Ther. 2023; 13(1):1-9.
PMID: 37982988 PMC: 10787707. DOI: 10.1007/s40120-023-00559-5.
Treatment Patterns by Race and Ethnicity in Newly Diagnosed Persons with Multiple Sclerosis.
Geiger C, Sheinson D, To T, Jones D, Bonine N Drugs Real World Outcomes. 2023; 10(4):565-575.
PMID: 37733192 PMC: 10730787. DOI: 10.1007/s40801-023-00387-x.